



Practitioner's Docket No. 1059.00051

Image

1647

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: Dexian Dou, et al.

Serial Number: 09/914,277

Group Art Unit: 1647

Filed: March 25, 2002

For: ANTI-ANGIOGENIC KRINGLE PROTEIN AND ITS MUTANT

TRANSMITTAL OF SECOND SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR 1.97(e)(1)

Mail Stop DD
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Provided herewith are copies of patents and publications as listed in the attached PTO-1449 (supplemental).

Each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application mailed not more than three months prior to the filing of the statement. 37 CFR 1.97(e)(1).

While the statement may be "material" pursuant to 37 CFR 1.56, it is not intended to constitute an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such. The filing of this statement does not mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists.

Please charge our Deposit Account No. 11-1449 for any additional fees or credit our account for any overpayment. **A duplicate of this transmittal is attached.**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington

D.C. 20231, on

9/8/03
(Date of Deposit)

Angel Webb

Signature

9/8/03
Date of Signature

Respectfully submitted,

KOHN & ASSOCIATES, PLLC

Kenneth I. Kohn
Registration No. 30,955
30500 Northwestern Hwy.
Suite 410
Farmington Hills, MI 48334
(248) 539-5050



MANUAL OF PATENT EXAMINING PROCEDURE

Sheet 1 of 2

Form PTO-1449		Docket Number (Optional) 1059.00051	Application Number 09/914,277
SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant Dexian Dou, et al.	
		Filing Date 03/25/02	Group Art Unit 1647

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

	DOCKET NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

	Ault GS, Ryschkewitsch CF, Stoner GL. TYPE-SPECIFIC AMPLIFICATION OF VIRAL DNA USING TOUCHDOWN AND HOT START PCR, Journal of Virological Methods 1994, 46(2):145-156.
	Bicknell R, Harris AL. MECHANISMS AND THERAPEUTIC IMPLICATIONS OF ANGIOGENESIS, Current Opinion in Oncology 1996, 8:60-65.
	Browne ML et al. EXPRESSION OF RECOMBINANT HUMAN PLASMINOGEN AND AGLYCOPLASMINOGEN IN HeLa CELLS, Fibrinolysis 1991, Vol 5(4), 257-260.
	Dameron KM, Volpert OV, Tainsky MA, Bouck N. CONTROL OF ANGIOGENESIS ON FIBROBLASTS BY p53 REGULATION OF THROMBOSPONDIN-1, Science 1994; 265:1582-1584.
	Fisher B, Gunduz N, Coyle J, Rudock C, Saffer EA. PRESENCE OF A GROWTH-STIMULATING FACTOR IN SERUM FOLLOWING PRIMARY TUMOR REMOVAL IN MICE, Cancer Research 1989, 49:1996-2001.
	Folkman I, Sing Y. ANGIOGENESIS, Biol Chem 1992, 267:10931.
	Folkman J, Haudenschild CC, Zetter BR. LONG-TERM CULTURE OF CAPILLARY ENDOTHELIAL CELLS, Proc Natl Acad Sci USA 1979, 76:5217-5221.
	Folkman J. ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE, Nature Medicine 1995, 1(1):27-31.
	Folkman J. TUMOR ANGIOGENESIS: THERAPEUTIC IMPLICATIONS, N. Eng J Med 285:1182.
	Gately S, Twardowski P, Stack MS, Cundiff DL, Grella D, Castellino FJ, Enghild J, Kwaan HC, Lee F, Kramer RA, Volpert O, Bouck N, Soff GA. THE MECHANISM OF CANCER-MEDIATED CONVERSION OF PLASMINOGEN TO THE ANGIOGENESIS INHIBITOR ANGIOSTATIN, Proceedings of the National Academy of Sciences of the United States of America, 1997, 94(20):10868-10872.
	Kohn EC, Liotta La. MOLECULAR INSIGHTS INTO CANCER INVASION: STRATEGIES FOR PREVENTION AND INTERVENTION, Cancer Res 1995, 55:1856-1860.
	Liotta LA, Kleinerman J, Saidel G. QUANTITATIVE RELATIONSHIPS OF INTRAVASCULAR TUMOR CELLS: TUMOR VESSELS AND PULMONARY METASTASES FOLLOWING TUMOR IMPLANTATION, Cancer Res 1974, 34:997-1003.
	Lokker NA, Presta LG, Godowski PJ. MUTATIONAL ANALYSIS AND MOLECULAR MODELING OF THE N-t KRINGLE-CONTAINING DOMAIN OF HEPATOCYTE GROWTH FACTOR IDENTIFIES AMINO ACID SIDE CHAINS IMPORTANT FOR INTERACTION WITH THE c-Met RECEPTOR, Protein Engineering 1994, 7(7):895-903.
	Maione T, Gray GS, Petro AJ, Hunt AJ, Donner AL, Bauer SI, Carson HF, Sharpe RJ. INHIBITION OF ANGIOGENESIS BY RECOMBINANT HUMAN PLATELET FACTOR-4 AND RELATED PEPTIDES, Science 1990, 247:77-79.
	Mikkelsen T, Yan PS, Ho KL, Sameni M, Sloane BF, Rosenblum ML. IMMUNOLOCALIZATION OF CATHESPIN B IN HUMAN GLIOMA: IMPLICATIONS FOR TUMOR INVASION AND ANGIOGENESIS, Neurosurg. 1995, 83:285-290.

SEARCHED
INDEXED
SERIALIZED
FILED
OCT 1 1993
U.S. PATENT & TRADEMARK OFFICE

	Mulder M, Kohnert U, Fischer S, van Hinsbergh VW, Verheijen JH. THE INTERACTION OF RECOMBINANT TISSUE TYPE PLASMINOGEN ACTIVATOR AND RECOMBINANT PLASMINOGEN ACTIVATOR (r-PA/BM 06.022) WITH HUMAN ENDOTHELIAL CELLS, <i>Blood Coagulation and Fibrinolysis</i> 1997, 8:124-133.
	Nelson J, Allen W, Scott W, Bailie J, Walker B, McFerran N, Wilson, D. MURINE EPIDERMAL GROWTH FACTOR (EGF) FRAGMENT (33-42) INHIBITS BOTH EGF- AND LAMININ-DEPENDENT ENDOTHELIAL CELL MOTILITY AND ANGIOGENESIS, <i>Cancer Research</i> 1995, 55:3772-3776.
	Nilsen SL, DeFord ME, Prorok M, Chibber BAK, Brethauer RK, Castellino FJ. HIGH-LEVEL SECRETION IN PICHIA PASTORIS AND BIOCHEMICAL CHARACTERIZATION OF THE RECOMBINANT KRINGLE 2 DOMAIN OF TISSUE-TYPE PLASMINOGEN ACTIVATOR, <i>Biotechnol Appl Biochem</i> 1997, 25:63-74.
	Pennica D, Holmes, WE, Kohr WJ, Harkins RN, Vehar GA, Ward CA, Bennett WF, Yelverton E, Seeburg PH, Heyneker HL, Goeddel DV, Colleen D. CLONING AND EXPRESSION OF HUMAN TISSUE-TYPE PLASMINOGEN ACTIVATOR cDNA IN <i>E. coli</i> , <i>Nature</i> 1983, 301:214-221.
	Perbal. A PRACTICAL GUIDE TO MOLECULAR CLONING, John Wiley & Sons, New York 1988.
	Polverini PJ, Bouck NP, Rastinejad F. ASSAY AND PURIFICATION OF NATURALLY OCCURRING INHIBITOR OF ANGIOGENESIS. <i>Methods Enzymol</i> 1991, 198:440-450.
	Rodriguez, RL and Denhardt DT, eds. VECTORS: A SURVEY OF MOLECULAR CLONING VECTORS AND THEIR USES, Butterworths, Boston, MA 1988.
	Sanger F, Air GM, Barrell BG, Brown NL, Coulson AR, Fiddes CA, Hutchison CA, Cloccombe PM, Smith M. NUCLIOTIDE SEQUENCE OF BACTERIOPHAGE PHI X174 DNA, <i>Nature</i> 1977, 265(5596):687-695.
	Simpson-Herren L, Sanford AH, Holmquist JP. EFFECTS OF SURGERY ON THE CELL KINETICS ON RESIDUAL TUMOR, <i>Cancer Treat. Rep.</i> 1976, 60:1749-1760.
	Tolsma SS, Volpert OV, Good DJ, Frazier WA, Polverini PJ, Bouck N. PEPTIDES DERIVED FROM TWO SEPARATE DOMAINS OF THE MATRIX PROTEIN THROMBOSPONDIN-1 HAVE ANTI-ANGIOGENIC ACTIVITY, <i>Journal of Cell Biology</i> 1993, Vol. 122, No. 2, pgs 497-511.
	Topol EJ, Califf RM, George BS, Caracas DJ, Lee KL. INSIGHTS DERIVED FROM THE THROMBOLYSIS AND ANGIOPLASTY IN MYOCARDIAL INFARCTION (TAMI) Trials, <i>Journal of the American College of Cardiology</i> 1988, 12(6 Suppl. A):24A-31A.
	Urano T, Takada Y, Takada A. STIMULATION OF THE AMIDOLYTIC ACTIVITY OF SINGLE CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR BY FIBRINOGEN DEGRADATION PRODUCT: POSSIBLE FIBRIN BINDING SITES ON SINGLE CHAIN TISSUE-TYPE PLASMINOGEN ACTIVATOR MOLECULE, <i>Biochimica et Biophysica Acta</i> 1991, 1077:245-252.
	Vega et al. GENE TARGETING, CRC Press, Ann Arbor, MI 1995.
	Watson et al. RECOMBINANT DNA, Scientific American Books, New York.
	Wilson C, Goberdhan DC, Steller H, Dror. A POTENTIAL NEUTROTROPHIC RECEPTOR GENE, ENCODES A DROSOPHILA HOMOLOG OF THE VERTEBRATE Ror FAMILY OF Trk-RELATED RECEPTOR TYROSINE KINASES, <i>Proceedings of the National Academy of Sciences of the United States of America</i> 1993, 90(15):7109-7113.
EXAMINER	DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.